Opens in a new tab

Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 22 December 2025)

Date22 December 2025
CourtCoA
DivisionLuxembourg (LU)
Type of actionApplication RoP262.1 (b)
Case number(s)UPC_CoA_886/2025
Registry referenceUPC-COA-0000886/2025
PartiesHerbert Smith Freehills Kramer LLP (applicant) in Insulet Corporation v. EOFLow Co., Ltd.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

The judge-rapporteur of the Court of Appeal, sitting alone, grants Herbert Smith Freehills Kramer LLP access to Insulet Corporation’s Statement of Appeal and to a redacted version of EOFLow Co., Ltd.’s Statement of Response in appeal UPC_CoA_768/2024 (EP 4 201 327), decided by an order of 30 April 2025 on appeal from an order of the Milan Central Division. Three days after access was refused to a database publisher in Sumi Agro v Syngenta, the Court confirms that a law firm may be a member of the public within Rule 262.1(b) RoP, even where its request has a commercial dimension.

Question

Does a law firm seeking to understand a decision in order to advise its clients better have a sufficient interest in access to the pleadings, with no identified third party behind its request?

Decision

A law firm may be a member of the public within Rule 262.1(b) RoP, without any bona fide third party standing behind its application. Scrutinising how the Court handled the dispute enhances its ability to advise and serves the Court and its users (paragraphs 9 and 10). The interest relied on matches the general interest recognised in Ocado, which arises once a decision has been given (paragraph 11). Pursuing commercial interests does not preclude access, as the applicant does not commercialise the documents, and copyright is not an interest to be protected under Art. 45 UPCA (paragraphs 13 and 14). Personal data are redacted, and EOFLow’s confidentiality interests are preserved by access to the redacted version only (paragraphs 15 to 17). Insulet’s request that the applicant bear the costs is rejected (paragraphs 18 and 19).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 10(1), 45, 58 and 69(3)
Rules of Procedure
Rules 262.1, 262.2 and 262A
Other provisions
Regulation (EU) 2016/679.
Case law cited
Ocado, Court of Appeal, 10 April 2024, UPC_CoA_404/2023, Abbott v Powell Gilbert, Court of Appeal, UPC_CoA_480/2024 and UPC_CoA_481/2024, Docket Navigator v Sumi Agro and Syngenta, Court of Appeal, 19 December 2025, UPC_CoA_523/2024.

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_886/2025 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
L’accès à la déclaration d’appel et à la version caviardée du mémoire en réponse est accordé au cabinet demandeur. Un cabinet d’avocats est un membre du public et la demande d’Insulet sur les frais est rejetée.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.